When it comes to treating psoriasis in older patients, the landscape is surprisingly optimistic. Who would’ve thought that biologics could actually be a game changer for the elderly? Turns out, these treatments can deliver results comparable to those seen in younger patients. In fact, over half of the elderly patients on bimekizumab achieved complete skin clearance by week 16. Yes, that’s right! And they didn’t just clear up the usual areas; they tackled those stubborn spots on the scalp, palms, and nails, too.
Now, let’s talk safety. Most biologics have a pretty favorable safety profile in older patients. Shocking, I know! There’s no significant uptick in serious adverse events compared to younger folks. Most side effects are mild – think eczema or a little oral candidiasis. Sounds manageable, right? Additionally, Bimekizumab’s safety profile was particularly impressive, with only 5.1% of participants reporting adverse events. Moreover, the overall safety profiles remained similar despite more comorbidities in older patients, which is a reassuring finding.
Most biologics boast a favorable safety profile for older patients, with mild side effects being the norm. Sounds pretty manageable, right?
And let’s be real, serious adverse events leading to drug discontinuation are rare in older adults.
But wait, there’s more! The risk of infections with biologics? Minimal. Some might even argue that certain biologics protect against infections in older patients. Imagine that! No one wants to sit around worrying about infections while managing psoriasis.
However, not everything is sunshine and rainbows. Drug survival rates drop in older patients, especially with adalimumab. One-year survival for this drug is 81% in elderly patients versus 99% in younger ones. That’s a hefty difference.
But hey, this could be due to comorbidities or treatment switches rather than the drugs themselves.
And let’s not forget that common comorbidities like obesity or diabetes don’t seem to affect the efficacy or safety of biologics much. So, the takeaway? Biologics can provide hope for older patients battling psoriasis. It’s not just a pipe dream; it’s a reality that’s proving to be rather hopeful.
